Search: onr:"swepub:oai:prod.swepub.kib.ki.se:144614116" >
Guidance for the Ma...
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
-
Gerotziafas, GT (author)
-
Catalano, M (author)
-
Colgan, MP (author)
-
show more...
-
Pecsvarady, Z (author)
-
Wautrecht, JC (author)
-
Fazeli, B (author)
-
Olinic, DM (author)
-
Farkas, K (author)
-
Elalamy, I (author)
-
Falanga, A (author)
-
Fareed, J (author)
-
Papageorgiou, C (author)
-
Arellano, RS (author)
-
Agathagelou, P (author)
-
Antic, D (author)
-
Auad, L (author)
-
Banfic, L (author)
-
Bartolomew, JR (author)
-
Benczur, B (author)
-
Bernardo, MB (author)
-
Boccardo, F (author)
-
Cifkova, R (author)
-
Cosmi, B (author)
-
De Marchi, S (author)
-
Dimakakos, E (author)
-
Dimopoulos, MA (author)
-
Dimitrov, G (author)
-
Durand-Zaleski, I (author)
-
Edmonds, M (author)
-
El Nazar, EA (author)
-
Erer, D (author)
-
Esponda, OL (author)
-
Gresele, P (author)
-
Gschwandtner, M (author)
-
Gu, YQ (author)
-
Heinzmann, M (author)
-
Hamburg, NM (author)
-
Hamade, A (author)
-
Jatoi, NA (author)
-
Karahan, O (author)
-
Karetova, D (author)
-
Karplus, T (author)
-
Klein-Weigel, P (author)
-
Kolossvary, E (author)
-
Kozak, M (author)
-
Lefkou, E (author)
-
Lessiani, G (author)
-
Liew, A (author)
-
Marcoccia, A (author)
-
Marshang, P (author)
-
Marakomichelakis, G (author)
-
Matuska, J (author)
-
Moraglia, L (author)
-
Pillon, S (author)
-
Poredos, P (author)
-
Prior, M (author)
-
Salvador, DRK (author)
-
Schlager, O (author)
-
Schernthaner, G (author)
-
Sieron, A (author)
-
- Spaak, J (author)
- Karolinska Institutet
-
Spyropoulos, A (author)
-
Sprynger, M (author)
-
Suput, D (author)
-
Stanek, A (author)
-
Stvrtinova, V (author)
-
Szuba, A (author)
-
Tafur, A (author)
-
Vandreden, P (author)
-
Vardas, PE (author)
-
Vasic, D (author)
-
Vikkula, M (author)
-
Wennberg, P (author)
-
Zhai, ZG (author)
-
show less...
-
(creator_code:org_t)
- 2020-09-13
- 2020
- English.
-
In: Thrombosis and haemostasis. - : Georg Thieme Verlag KG. - 2567-689X .- 0340-6245. ; 120:12, s. 1597-1628
- Related links:
-
http://www.thieme-co...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Gerotziafas, GT
-
Catalano, M
-
Colgan, MP
-
Pecsvarady, Z
-
Wautrecht, JC
-
Fazeli, B
-
show more...
-
Olinic, DM
-
Farkas, K
-
Elalamy, I
-
Falanga, A
-
Fareed, J
-
Papageorgiou, C
-
Arellano, RS
-
Agathagelou, P
-
Antic, D
-
Auad, L
-
Banfic, L
-
Bartolomew, JR
-
Benczur, B
-
Bernardo, MB
-
Boccardo, F
-
Cifkova, R
-
Cosmi, B
-
De Marchi, S
-
Dimakakos, E
-
Dimopoulos, MA
-
Dimitrov, G
-
Durand-Zaleski, ...
-
Edmonds, M
-
El Nazar, EA
-
Erer, D
-
Esponda, OL
-
Gresele, P
-
Gschwandtner, M
-
Gu, YQ
-
Heinzmann, M
-
Hamburg, NM
-
Hamade, A
-
Jatoi, NA
-
Karahan, O
-
Karetova, D
-
Karplus, T
-
Klein-Weigel, P
-
Kolossvary, E
-
Kozak, M
-
Lefkou, E
-
Lessiani, G
-
Liew, A
-
Marcoccia, A
-
Marshang, P
-
Marakomichelakis ...
-
Matuska, J
-
Moraglia, L
-
Pillon, S
-
Poredos, P
-
Prior, M
-
Salvador, DRK
-
Schlager, O
-
Schernthaner, G
-
Sieron, A
-
Spaak, J
-
Spyropoulos, A
-
Sprynger, M
-
Suput, D
-
Stanek, A
-
Stvrtinova, V
-
Szuba, A
-
Tafur, A
-
Vandreden, P
-
Vardas, PE
-
Vasic, D
-
Vikkula, M
-
Wennberg, P
-
Zhai, ZG
-
show less...
- Articles in the publication
-
Thrombosis and h ...
- By the university
-
Karolinska Institutet